Who is sponsoring NCT00898846?

NCT00898846 is sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan.

What condition does NCT00898846 study?

NCT00898846 studies Colorectal Cancer.

What drugs are being tested in NCT00898846?

Interventions: UFT adjuvant chemotherapy.

What is the status of NCT00898846?

NCT00898846 is currently COMPLETED.

Last reviewed 2016-09-26 · How we verify

Identification of the Prognostic Factors of Stage II Colon Cancer Patients Receiving Adjuvant Chemotherapy With UFT

NCT00898846 COMPLETED

RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict which patients will respond to treatment. PURPOSE: This laboratory study is looking at prognostic factors in patients receiving tegafur-uracil for stage II colon cancer that was completely removed by surgery.

Details

Lead sponsor	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Status	COMPLETED
Enrolment	1111
Start date	2006-10
Completion	2016-09

Conditions

Colorectal Cancer

Interventions

UFT adjuvant chemotherapy

Primary outcomes

mRNA levels — 9years
mRNA levels of patients are analyzed by the Danenberg tumor profile (DTP) method in the following indicators: thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), orotate phosphoribosyltransferase (OPRT), folylpolyglutamate synthetase (FPGS) vascular endothelial growth factor (VEGF), and cyclooxygenase-2 (Cox-2) mRNA levels.

Countries

Japan